دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 4,800,000 تومان- قیمت ویژه : 1,790,000تومان
پکیج دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
قیمت : 1,500,000 تومان- قیمت ویژه : 590,000تومان
Improving Clinical Decisions Through Primary Trial Data Review-The Regulatory Lens.
Rethinking Ribociclib Dosage and Use in the Era of Patient-Centered Oncology-When Less Is More.
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial.
Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer: A Systematic Review and Meta-Analysis.
Patient-Reported Outcomes-The Missing Variable in Survival Prediction.
Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Advanced Penile Cancer: The Nonrandomized HERCULES (LACOG 0218) Clinical Trial.
Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer.
Prostate-Specific Antigen Levels Among Participants Receiving Annual Testing.
Low-Dose Aspirin for Individualized Cancer Prevention in Older Adults: A Secondary Analysis of the ASPREE Randomized Clinical Trial.
600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial.
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Current Controversies and Challenges in Non-Oncogene-Addicted Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Review.
Limitations in Artificial Intelligence-Driven Patient-Centered Cancer Nursing Research.
Limitations in Artificial Intelligence-Driven Patient-Centered Cancer Nursing Research.
Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer.
Limitations in Artificial Intelligence-Driven Patient-Centered Cancer Nursing Research-Reply.
Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer.
Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer-Reply.
